A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer
- 1 March 1991
- journal article
- clinical trial
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 18, 47-55
- https://doi.org/10.1016/0305-7372(91)90024-t
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Role of Hexamethylmelamine in the Treatment of Ovarian Cancer: Where is the Needle in the Haystack?JNCI Journal of the National Cancer Institute, 1988
- Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trialCancer Chemotherapy and Pharmacology, 1985
- Hexamethylmelamine: An evaluation of its role in the treatment of ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1979
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinomaCancer, 1978
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Prolonged low-dosage administration of hexamethylmelamine (NC 13875)Cancer, 1970
- Phase II study of hexamethylmelamine (NSC 13875)Cancer, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Cyanuric Chloride Derivatives. II. Substituted MelaminesJournal of the American Chemical Society, 1951